Uppsala, Sweden, 2009-08-28
PRESS RELEASE
This press release may not be published or distributed, directly or indirectly,
in or to the United States of America, Canada, Japan, Australia, New Zealand, or
any other country where such action is wholly or partially subject to legal
restrictions. Nor may the information in this press release be forwarded,
reproduced or disclosed in such a manner that contravenes such restrictions.
This press release does not contain or constitute an invitation or an offer to
acquire, subscribe for or otherwise trade in shares, subscription rights or
other securities in Oasmia Pharmaceutical AB (publ) ("Oasmia").
Oasmia's rights issue fully subscribed
The interest in the share issue with preferential rights for existing
shareholders (the “Rights Issue”), which was closed on 24 August 2009, was great
and exceeded the total issue volume. The result of the Rights Issue was that
2 392 858 shares has been allotted and subscribed for whereby Oasmia is provided
with SEK 59.8 million before deduction of issue related costs. Approximately
88.5 percent of the Rights Issue has been subscribed for through the exercise of
subscription rights and approximately 11.5 percent without the exercise of
subscription rights. The board of directors has resolved on the allotment of
those shares subscribed for without the exercise of subscription rights in
accordance with the terms described in the issue prospectus.
The shares that Oasmia's principal owner, Oasmia S.A., subscribed for in the
Rights Issue have been paid for in part through set-off against existing loans
in the amount of SEK 28.7 million. Oasmia's debt to Oasmia S.A. has thus been
re-paid in full.
The Rights Issue will increase the share capital in Oasmia by SEK 239,285.80.
After the completion of the Rights Issue, the total number of shares outstanding
will be 35,892,858 and the share capital will be SEK 3,589,285.80. Paid-up
subscribed shares (Sw. betalda tecknade aktier, BTA) will be replaced with new
shares as soon as the increase in the share capital has been registered by the
Swedish Companies Registration Office (Sw. Bolagsverket).
About Oasmia
Oasmia Pharmaceutical AB develops second and third generation cancer drugs based
on nanotechnology for human and veterinary use. The broad portfolio is focused
on oncology and contains several promising products in clinical and pre-clinical
phase. Oasmia cooperates with leading universities and other biotech companies
to discover and optimize substances with a favourable safety profile and better
efficacy. The company name was registered in 1999 and is based in Uppsala,
Sweden.
For more information, please contact: Maria Lundén, Head of Public Relations,
Oasmia Pharmaceutical AB.
E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also
available at www.ngm.se and www.oasmia.com
